FAP, June 1 / PRNewswire-FirstCall-Asianet /-- Pril Pharmaceuticals announced that the company has recently received a license to market vancomycin hydrochloride 500mg and 1g for injection issued by the Australian Drug Administration (TGA). Vancomycin hydrochloride is used to treat severe infections caused by methicillin-resistant (β-lactam) staphylococcal sensitive strains.